Takeda appoints Rhonda Pacheco to lead its U.S. business, leveraging her experience with Zepbound’s launch.
Author: PharmaSignal News Desk
Novo Nordisk layoffs affect 9,000 employees globally as part of restructuring to address obesity drug competition.
Merck cancels London lab plans, citing $1.3B investment issues and lack of UK government progress.
FDA pig organ trial to start next year, advancing gene-edited organs in humans. Key step in transplantation.
Sanofi stock drop over 10% after Amlitelimab Phase III results raises concerns about future pipeline and Dupixent patent expiration.
Avadel XWPharma partnership secures global rights to valiloxybate, targeting narcolepsy and idiopathic hypersomnia.
FDA rejection letters will be released soon after issuance, enhancing transparency in the drug review process.
WHO essential medicines list now includes cancer and diabetes drugs, adding 20 new medicines for adults and 15 for children.
Enlaza Vertex collaboration forms a $2.4 billion deal to advance autoimmune therapies using War-Lock technology.
Servier Fragile X acquisition involves KER-0193, enhancing its neurology pipeline with a $450m deal.